Login to Your Account



Neuropharm Raises £20M To Fund CNS Development Pipeline

By Nuala Moran


Wednesday, March 7, 2007
LONDON - Neuropharm Group plc raised £20 million (US$38.4 million) in a listing on London's Alternative Investment Market, enabling it to attempt to take Prozac as a treatment for autism through to market and advance the clinical development of three other products for treating pediatric central nervous system disorders. (BioWorld International)

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription